Published in Biotech Business Week, May 19th, 2003
"This program reaffirms our member companies' commitment to the highest standards of drug quality and patient safety," said Alan F. Holmer, president of PhRMA. "The information provided by PhRMA members under this program will assist FDA in carrying out its responsibilities to protect the safety and integrity of the nation's drug supply by quickly and effectively removing counterfeit drugs from the marketplace."
Under the voluntary program, PhRMA member companies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.